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Abstract: This paper presents the design and implementation of databases in pharmacy, points out the most common problems 
that may be encountered, and describes practical solutions. The paper also describes the structure in terms of linking multiple 
applications to one single database in terms of achieving business automation.
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INTRODUCTION  
When talking about pharmacy one immediately 
thinks of the drug, the pharmacist, and the patient. 
Complexity in this area of healthcare is evident, since 
pharmaceuticals requires a good knowledge of chem-
istry and the human being itself. This brings us to 
another question: is it possible to record data in this 
ϐield and in what way? This area is being much more 
regulated lately, with the development of new inter-
national standards and regulations. The answer leads 
us to three possible segmentations of records.
One of the records is the record of medicines 
that can be marketed in the country (for which the 
record is being made), the second is the record of 
healthcare system patients’, and the third record 
is the record of professionals, which in our case is 
a graduated pharmacist or a master of pharmacy. 
Namely, through the institution’s registries certain 
records of these professionals are being created. In 
the recent history, we have had a situation where 
we have lacked this personnel and this record was 
very important because it prevented the misuse of 
a pharmacist’s professional qualiϐication license. 
Theoretically, it could happen that one graduated 
pharmacist worked full-time jobs in 3 wholesales in 
3 different cities, which is impossible in practice.
To automate logging in this area, software’s with 
various solutions are created. These software’s are 
made up of an application and databases from which 
applications pull data and enter new or modify ex-
isting ones.
LEGAL REGULATIONS AND STANDARDS
In order to become familiar with the subject of 
the inspection and construction of the database, we 
need to familiarize ourselves with the relevant legis-
lation and standards in the Bosnia and Herzegovina.
Bosnia and Herzegovina is regulated in such a 
way that the national Agency for Medicinal Products 
and Medical Devices of Bosnia and Herzegovina con-
trols the manufacturing, transportation and whole-
sale distribution of medicines and medical devices, 
while the entity ministries and the Brcko District 
control the retail sale.
Relevant national legislation in Bosnia and Her-
zegovina includes:[2]
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• Law on Medicines and Medical Devices (Of-
ϐicial Gazette of Bosnia and Herzegovina, No. 
58/08);
• Rulebook on the Type, Amount and Method of 
Payment of Expenses for Performing the Ac-
tivities of the Agency for Medicinal Products 
and Medical Devices of Bosnia and Herzegov-
ina (“Ofϐicial Gazette of Bosnia and Herzegov-
ina”, No. 70/09);
• Order on payment account for payment of 
costs provided by the Law on Medicinal Prod-
ucts and Medical Devices (“Ofϐicial Gazette of 
Bosnia and Herzegovina”, No. 72/09);
• Order on Amendments to the Payment Ac-
counts for Administrative Fees (Ofϐicial Ga-
zette of Bosnia and Herzegovina No. 84/13);
• Rulebook on Manner of Quality Control of Me-
dicinal Products (“Ofϐicial Gazette of Bosnia 
and Herzegovina”, No. 97/09);
• Rulebook on the manner of monitoring de-
fects in the quality of the medicinal product 
(Ofϐicial Gazette of Bosnia and Herzegovina, 
No. 97/09);
• Rulebook on Clinical Trials of Medicines and 
Medical Devices (“Ofϐicial Gazette of Bosnia 
and Herzegovina”, No. 4/10);
• Rulebook on Medical Devices (Ofϐicial Gazette 
of Bosnia and Herzegovina, No. 4/10);
• Rulebook on Procedure and Manner of Grant-
ing Marketing Authorization (“Ofϐicial Gazette 
of Bosnia and Herzegovina”, No. 75/11);
• Rulebook on Good Manufacturing Practice 
(GMP) for Medicines (“Ofϐicial Gazette of Bos-
nia and Herzegovina”, No. 24/10);
• Rulebook on the manner of advertising medi-
cines and medical devices (“Ofϐicial Gazette of 
Bosnia and Herzegovina”, No. 40/10);
• Rulebook on the Content and Method of La-
beling of the Outer and Inner Packaging of the 
medicinal product (Ofϐicial Gazette of Bosnia 
and Herzegovina, No. 40/10);
• Rulebook on Conditions, Circumstances and 
Procedure for Engaging Authorized Labora-
tories (“Ofϐicial Gazette of Bosnia and Herze-
govina”, No. 60/10);
• Decision on the manner and scope of imple-
mentation / selection of parameters for quali-
ty control of each batch of imported medicinal 
product (Ofϐicial Gazette of Bosnia and Herze-
govina No. 60/10);
• Rulebook on the Method of Conducting Phar-
maceutical Inspection (Ofϐicial Gazette of Bos-
nia and Herzegovina, No. 23/11);
• Ordinance on the disposal of pharmaceutical 
waste (Ofϐicial Gazette of Bosnia and Herze-
govina, No. 23/11);
• Rulebook on Conditions for Importation of 
Medicines Not Authorized for Marketing in 
Bosnia and Herzegovina (“Ofϐicial Gazette of 
Bosnia and Herzegovina”, No. 23/11);
• Rulebook on Pharmaceutical Inspector Exams 
(“Ofϐicial Gazette of Bosnia and Herzegovina”, 
No. 59/11);
• Decision on the program and content of the 
Pharmaceutical Inspector exam;
• Decision on the procedure for obtaining a 
license for the import of risk medicines li-
censed for placing on the market in Bosnia 
and Herzegovina (“Ofϐicial Gazette of Bosnia 
and Herzegovina”, No. 23/11);
• Medicines and Medical Devices Policy in Bos-
nia and Herzegovina (“Ofϐicial Gazette of Bos-
nia and Herzegovina”, No. 55/11);
• Rulebook on the manner of reporting, col-
lecting and monitoring adverse reactions to 
medicinal products (Ofϐicial Gazette of Bosnia 
and Herzegovina, No. 58/12);
• Rulebook on monitoring of adverse events re-
lated to medical devices (vigilance of medical 
devices) (“Ofϐicial Gazette of Bosnia and Her-
zegovina”, No. 58/12);
• Guidelines for Good Clinical Practice in Clini-
cal Trials (“Ofϐicial Gazette of Bosnia and Her-
zegovina”, No. 19/12);
• Rulebook on the Manufacture and Wholesale 
of Medical Devices (“Ofϐicial Gazette of Bosnia 
and Herzegovina”, No. 71/12);
• Corrigendum to the Rulebook on Manufac-
ture and Wholesale of Medical Devices (“Of-
ϐicial Gazette of Bosnia and Herzegovina”, No. 
64/13);
• Rulebook on Amendments to the Rulebook 
on the Content and Method of Labeling of the 
Outer and Inner Packaging of the medicinal 
product (Ofϐicial Gazette of Bosnia and Herze-
govina, No. 36/13);
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• Rulebook on Good Distribution Practice 
(GDP) for Medicinal Products for Human Use 
(“Ofϐicial Gazette of Bosnia and Herzegovina”, 
No. 75/13);
• Decision of the Expert Council on Delaying the 
Application of Data Exclusivity (Ofϐicial Ga-
zette of Bosnia and Herzegovina, No. 57/13);
• Rulebook on Conditions for Carriage of Whole-
sale Medicines (“Ofϐicial Gazette of Bosnia and 
Herzegovina”, No. 49/14);
• Instruction on the procedure for import of 
medicinal products and medical devices of 
humanitarian character for the territories of 
Bosnia and Herzegovina endangered by natu-
ral or other disasters;
• Rulebook on the Method and Procedure for 
Classifying Medicines (“Ofϐicial Gazette of 
Bosnia and Herzegovina”, No. 69/14);
• Rulebook on Conditions for Production of Me-
dicinal Products (“Ofϐicial Gazette of Bosnia 
and Herzegovina”, No. 73/14);
• Rulebook on the method of price control, the 
method of pricing medicines and the manner 
of reporting drug prices in Bosnia and Herze-
govina (“Ofϐicial Gazette of Bosnia and Herze-
govina”, No. 3/17);
• RULES ON GOOD MANUFACTURING PRAC-
TICES FOR MEDICAL GAS (Ofϐicial Gazette of 
Bosnia and Herzegovina No. 49/18);
• RULES ON GOOD DISTRIBUTION PRACTICE 
(GDP) OF MEDICAL RESOURCES (“Ofϐicial Ga-
zette of Bosnia and Herzegovina”, No. 75/18);
• Law on Prevention and Suppression of Nar-
cotic Drug Abuse (Ofϐicial Gazette of Bosnia 
and Herzegovina, No. 8/06) - with lists;
• Decision on the Designation of Internation-
al Border Crossings for the Transboundary 
Movement of Substances and Plants in Tables 
II, III and IV of the List of Narcotic Drugs, Psy-
chotropic suspensions, Narcotic Drugs and 
Precursors (Ofϐicial Gazette of Bosnia and 
Herzegovina, No. 58/08 );
• Decision on amendments to the list of narcotic 
drugs, psychotropic substances, plants from 
which narcotic drugs can be obtained and pre-
cursors (“Ofϐicial Gazette of Bosnia and Her-
zegovina”, No. 103/08);
• Decision on amendments to the list of narcotic 
drugs, psychotropic substances, plants from 
which narcotic drugs can be obtained and pre-
cursors (“Ofϐicial Gazette of Bosnia and Her-
zegovina”, No. 51/11);
• Decision to exempt preparations from the ap-
plication of control measures (Ofϐicial Gazette 
of Bosnia and Herzegovina, No. 20/10);
• Security requirements for issuing a license 
for the production and marketing of narcotic 
drugs and psychotropic substances (“Ofϐi-
cial Gazette of Bosnia and Herzegovina”, No. 
69/13).
In addition to these regulations, there are entity 
and Brcko District regulations.
The entity’s new responsibility is retailing and 
retail pricing towards end users, patients. Entity and 
Brcko District regulations are located at the follow-
ing links:
1. Brcko District [6]
2. Federation of Bosnia and Herzegovina [7]
3. Republic of Srpska [8] 
Standards and legislation applicable at national 
level include part of EU standards and regulations. 
In the EU countries European Medicines Agency 
(EMA) has competence in addition to national insti-
tutions.
The European Medicines Agency (EMA) is in the 
process of implementation of the standards devel-
oped by the International Organization for Stan-
dardization (ISO) for the identiϐication of medicinal 
products (IDMP).
The ISO IDMP standards specify the use of stan-
dardized deϐinitions for the identiϐication and de-
scription of medicinal products for human use.
Their purpose is to facilitate the reliable ex-
change of medicinal products’ information in a ro-
bust and consistent manner. They help to ensure 
wide interoperability across global regulatory and 
healthcare communities, which is critical in ensur-
ing accurate analysis and unambiguous communica-
tion across jurisdictions.
Commission Implementing Regulation (EU) No 
520/2012 (articles 25 and 26) obliges European 
Union (EU) Member States, marketing authorization 
holders and EMA to use the ISO IDMP standards. 
This will affect many areas of the pharmaceutical 
regulatory environment, both in the EU and other 
regions.
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Scope of the ISO IDMP standards [3]
The ϐive standards provide data elements and 
structures to uniquely identify and exchange infor-
mation about:
• substances (ISO 11238);
• pharmaceutical dose forms, units of presenta-
tion, routes of administration and packaging 
(ISO 11239):
• units of measurement (ISO 11240);
• regulated pharmaceutical product informa-
tion (ISO 11616);
• regulated medicinal product information (ISO 
11615).
These standards cover the following to describe 
a medicinal product for human use:
• medicinal product name;
• active substances;






Medical devices are products or equipment in-
tended generally for a medical use. They are regu-
lated by the national competent authorities, but the 
European Medicines Agency (EMA) is also involved 
in the assessment of certain categories of medical 
device under European Union (EU) legislation.
The adoption of Regulation (EU) 2017/745 
on Medical Devices (MDR) and Regulation (EU) 
2017/746 on In-Vitro Diagnostic Devices (IVDR) 
changed the European legal framework for medical 
devices, introducing new responsibilities for EMA 
and for the national authorities. Both Regulations 
entered into force in the May 2017 and have a stag-
gered transitional period.
The MDR has a transition period of three years 
and will fully apply from 26th May 2020. The IVDR 
has a transition period of ϐive years and will fully ap-
ply from 26th May 2022.
During the transition period, manufacturers can 
place devices on the market under the currently ap-
plicable EU Directives (93/42/EEC, 98/79/EC and 
90/385/EEC) or under the new Regulations if they 
fully comply with these. [4].
Picture 1. Page 6 of presentation Introduction to SPOR data 
services Source: https://www.ema.europa.eu/en/documents/
presentation/presentation-introduction-spor-data-services_en.
pdf  visited: 11/28/2019. [5]
DESIGNING DATABASES
The tools I used to create the database are an MS-
SQL server with MS SQL Management Studio, MS 
Access with ODBC drivers for connecting to the da-
tabase and data loading. In addition, I used MS Excel 
to purify the data and to plan the construction of the 
database by normalizing it. This enabled the Excel 
worksheet visibility of the duplicated data and thus 
prevented duplication of records in the database. 
This web-based solution for Internet data display-
ing via a web server currently captures read-only 
database data.
The ϐirst version of the database contained an ap-
plication with a database that included institution’s 
registries. The database of this application is on the 
MSSQL platform, while the application in Access 
pulls data through the ODBC driver.
A second database was then implemented on the 
MYSQL platform with an application that was writ-
ten in the PHP programming language. The latter 
database and application belong to the Inspectorate 
and was separated from the former for the conϐiden-
tiality reasons. This led to the need for data reload 
due to the different technology used for the applica-
tion and due to the disconnection of the databases 
themselves.
Reports were extracted from the application ϐirst 
and second for the website and periodically modi-
ϐied in PDF format.
The basic idea for the reconstruction of the da-
tabase and the accompanying applications, was 
to create 3 applications with a common database, 
where everyone could use their part, which will be 
visible to him and will have the possibility to update 
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in the required segment of the database. In addition, 
a third application will be used to capture the data 
and display it on the website automatically after the 
data input.
In this way, we will avoid tipping over and enable 
more efϐicient business operations, while achieving 
automation of the business process. This transition 
will take place in 4 phases.
The ϐirst phase will be data puriϐication, upgrade 
and preparation of the database design according to 
user development requirements.
Picture 2. Phase 1, consolidation and cleaning data
The second phase will be the reconstruction of 
the existing database by adding an inspection data, 
with the migration of existing data.
Picture 3. Phase 2 database upgrade with inspection data 
migration
The third phase will be publishing of the data 
from MSSQL View via the PHP platform to the web 
site.
The fourth and the ϐinal phase will involve the 
creation of a web-based local application with local 
user authority segmentation.
Picture 5. Database width local web application and automatic 
web reporting data from database
After this phase, they could go a step further and 
enable online users to submit online applications. 
However, this requires further analysis due to the 
security aspect. Security testing is a type of software 
testing which purpose is detecting system’s vulner-
abilities. It checks whether the system data is pro-
tected from unauthorized access, during which data 
could be altered or deleted.[1]
Data input
With the data input we will divide basic data and 
inspection data.
Namely, the basic information entered by the of-
ϐicials is about the registration of a wholesale dis-
tributors or manufacturers of medicines or medical 
devices.
The inspector who performs the inspection of 
all these legal entities can see all the above-named 
data, and have possibility to modify them. He can 
also enter additional amount of data about inspec-
tion control, as well as the ordered measures. Fur-
ther upgrading of the database could allow the au-
tomatic download of data about the drugs from the 
Drug Database, or the automatic download of data 
about medical devices from the Medical Devices Da-
tabase. This is not currently automated, but there is 
possibility for further development of the base.
Processing
In order to compare the difference, I will show 
the main table.
Namely, in the ϐirst phase, this table contained 
almost all data about the legal entity. This later 
changed in such a way that only the basic data re-
mained, because the primary key rjesenjeID has 
taken other data from table Rjesenje that can be 
changed by the institution when changing the solu-
tion. In addition, the ϐield of inspection was added.
Picture 4. Phase 3 Same database width 2 application, and 
automatic web reporting site width data form database
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Table 1. MAIN TABLE Institution on Phase 1 – list of data
Name Field type Allowed blank Primary key
UstanovaID Int Unchecked yes
RegistarskiBroj Int Checked no
VrstaUstanoveID Int Checked no
Ustanova nvarchar(50) Checked no
Adresa nvarchar(50) Checked no
MjestoID Int Checked no
Telefon nvarchar(10) Checked no
Telefax nvarchar(10) Checked no
[E-mail] nvarchar(30) Checked no
BrojRjesenja nvarchar(21) Checked no
DatumRjesenja datetime Checked no
OblikSvojine nvarchar(100) Checked no
DatumPrestankaRada datetime Checked no
Napomena Ntext Checked no
Dokumentacija Ntext Checked no
IDStatus Int Checked no
USE [ru]
GO






 [UstanovaID] [int] IDENTITY(1,1) NOT NULL,
 [RegistarskiBroj] [int] NULL,
 [VrstaUstanoveID] [int] NULL,
 [Ustanova] [nvarchar](50) NULL,
 [Adresa] [nvarchar](50) NULL,
 [MjestoID] [int] NULL,
 [Telefon] [nvarchar](10) NULL,
 [Telefax] [nvarchar](10) NULL,
 [E-mail] [nvarchar](30) NULL,
 [BrojRjesenja] [nvarchar](21) NULL,
 [DatumRjesenja] [datetime] NULL,
 [OblikSvojine] [nvarchar](100) NULL,
 [DatumPrestankaRada] [datetime] NULL,
 [Napomena] [ntext] NULL,
 [Dokumentacija] [ntext] NULL,
 [IDStatus] [int] NULL,
 CONSTRAINT [PK_Ustanova] PRIMARY KEY CLUSTERED 
(
 [UstanovaID] ASC
)WITH (PAD_INDEX = OFF, STATISTICS_NORECOMPUTE = OFF, IGNORE_DUP_KEY = OFF, ALLOW_ROW_
LOCKS = ON, ALLOW_PAGE_LOCKS = ON) ON [PRIMARY]
) ON [PRIMARY] TEXTIMAGE_ON [PRIMARY]
GO
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Picture 6. Main table at database diagram - Phase 1
Table 2. MAIN TABLE Institution on Phase 2 – list of data
Name Field type Allowed blank Primary key
UstanovaID Int Unchecked yes
RegistarskiBroj Int Checked no
RjesenjeID Int Checked no
InspekcijaID Int Checked no
IDStatus Int Checked no
USE [ru]
GO
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CREATE TABLE [dbo].[Ustanova](
 [UstanovaID] [int] IDENTITY(1,1) NOT NULL,
 [RegistarskiBroj] [int] NULL,
 [RjesenjeID] [int] NULL,
 [InspekcijaID] [int] NULL,
 [IDStatus] [int] NULL,
 CONSTRAINT [PK_Ustanova] PRIMARY KEY CLUSTERED 
(
 [UstanovaID] ASC
)WITH (PAD_INDEX = OFF, STATISTICS_NORECOMPUTE = OFF, IGNORE_DUP_KEY = OFF, ALLOW_ROW_
LOCKS = ON, ALLOW_PAGE_LOCKS = ON) ON [PRIMARY]
) ON [PRIMARY]
GO




ALTER TABLE [dbo].[Ustanova] CHECK CONSTRAINT [FK_Ustanova_Mjesto]
GO




ALTER TABLE [dbo].[Ustanova] CHECK CONSTRAINT [FK_Ustanova_Status]
GO




ALTER TABLE [dbo].[Ustanova] CHECK CONSTRAINT [FK_Ustanova_Vrsta_Ustanove]
GO
Output data
The output contains a report.
We have four reports in the phase 1, but in the phase 2 we have 13 reports. In the phase 3 we 
have 14 reports.
List of reports in the phase 1:
1. REGISTRY OF DRUG MANUFACTURERS IN BOSNIA AND HERZEGOVINA
2. REGISTRY OF MEDICAL DEVICES MANUFACTURERS IN BOSNIA AND HERZEGOVINA
3. REGISTRY OF MEDICINAL PRODUCTS WHOLESALE DISTRIBUTORS IN BOSNIA AND 
HERZEGOVINA
4. REGISTRY OF MEDICAL DEVICES WHOLESALE DISTRIBUTORS IN BOSNIA AND HERZEGOVINA
List of reports in the phase 2:
1. REGISTRY OF DRUG MANUFACTURERS IN BOSNIA AND HERZEGOVINA
2. REGISTRY OF MEDICAL DEVICE MANUFACTURERS IN BOSNIA AND HERZEGOVINA LICENSED 
FOR THE CLASS I MEDICAL DEVICE MANUFACTURING AGENCY
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3. REGISTRY OF MEDICAL DEVICE MANUFACTURERS IN BOSNIA AND HERZEGOVINA AUTHORIZED 
FOR THE CLASS II MEDICAL DEVICE AND OTHER/LOWER CLASSES OF MEDICAL DEVICES 
MANUFACTURING
4. LIST OF RESPONSIBLE PERSONS FOR PLACING THE MEDICINE ON THE MARKET IN BOSNIA AND 
HERZEGOVINA
5. REGISTRY OF MEDICINAL PRODUCTS WHOLESALE DISTRIBUTORS WITH A LICENSE FOR 
IMPORT AND MARKETING OF MEDICINES IN BOSNIA AND HERZEGOVINA
6. REGISTRY OF MEDICINAL PRODUCTS WHOLESALE DISTRIBUTORS IN BOSNIA AND 
HERZEGOVINA WITH LICENSE FOR NATIONAL WHOLESALE
7. REGISTRY OF WHOLESALE DISTRIBUTORS AUTHORIZED TO WHOLESALE ALL MEDICINAL 
PRODUCTS
8. REGISTRY OF WHOLESALE DISTRIBUTORS AUTHORIZED FOR THE TRANSPORT OF MEDICAL 
DEVICES 
9. REGISTRY OF WHOLESALE DISTRIBUTORS AUTHORIZED FOR THE TRANSPORT OF CLASS I 
MEDICAL DEVICES 
10. REGISTRY OF WHOLESALE DISTRIBUTORS AUTHORIZED FOR THE TRANSPORT OF CLASS II 
MEDICAL DEVICES
11. REGISTRY OF WHOLESALE DISTRIBUTORS AUTHORIZED FOR THE TRANSPORT OF CLASS II AND 
OTHER LOWER CLASSES OF MEDICAL DEVICES
12. REGISTRY OF WHOLESALE DISTRIBUTORS AUTHORIZED SOLELY FOR THE TRANSPORT OF 
MEDICAL DEVICES
13. LEGAL ENTITIES WITH A PERMANENT OR TEMPORARY PROHIBITION OF ACTIVITIES
List of reports in phase 3:
1. REGISTRY OF DRUG MANUFACTURERS IN BOSNIA AND HERZEGOVINA
2. REGISTRY OF MEDICAL DEVICE MANUFACTURERS IN BOSNIA AND HERZEGOVINA LICENSED 
FOR THE CLASS I MEDICAL DEVICE MANUFACTURING AGENCY
3. REGISTRY OF MEDICAL DEVICE MANUFACTURERS IN BOSNIA AND HERZEGOVINA AUTHORIZED 
FOR THE CLASS II MEDICAL DEVICE AND OTHER/LOWER CLASSES OF MEDICAL DEVICES 
MANUFACTURING
4. LIST OF RESPONSIBLE PERSONS FOR PLACING THE MEDICINE ON THE MARKET IN BOSNIA AND 
HERZEGOVINA
5. REGISTRY OF MEDICINAL PRODUCTS WHOLESALE DISTRIBUTORS WITH A LICENSE FOR 
IMPORT AND MARKETING OF MEDICINES IN BOSNIA AND HERZEGOVINA
6. REGISTRY OF MEDICINAL PRODUCTS WHOLESALE DISTRIBUTORS IN BOSNIA AND 
HERZEGOVINA WITH LICENSE FOR NATIONAL WHOLESALE
7. REGISTRY OF  WHOLESALE DISTRIBUTORS AUTHORIZED TO WHOLESALE ALL MEDICINAL 
PRODUCTS
8. REGISTRY OF WHOLESALE DISTRIBUTORS AUTHORIZED FOR THE TRANSPORT OF MEDICAL 
DEVICES 
9. REGISTRY OF WHOLESALE DISTRIBUTORS AUTHORIZED FOR THE TRANSPORT OF CLASS I 
MEDICAL DEVICES 
10. REGISTRY OF WHOLESALE DISTRIBUTORS AUTHORIZED FOR THE TRANSPORT OF CLASS II 
MEDICAL DEVICES
11. REGISTRY OF WHOLESALE DISTRIBUTORS AUTHORIZED FOR THE TRANSPORT OF CLASS II AND 
OTHER LOWER CLASSES OF MEDICAL DEVICES
12. REGISTRY OF WHOLESALE DISTRIBUTORS AUTHORIZED SOLELY FOR THE TRANSPORT OF 
MEDICAL DEVICES
13. LEGAL ENTITIES WITH A PERMANENT OR TEMPORARY PROHIBITION OF ACTIVITIES
14. ADMINISTRATIVE PROHIBITION MEASURES IMPOSED DURING INSPECTION SUPERVISION AS OF 
01.01.2015
Registry of manufacturers of Medicinal Products in Bosnia and Herzegovina
SELECT UstanovaID, RegistarskiBroj, VrstaUstanoveID, Ustanova, Adresa, MjestoID, Telefon, 
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Telefax, [E-mail], BrojRjesenja, DatumRjesenja, OblikSvojine, DatumPrestankaRada, Napomena, 
Dokumentacija, IDStatus, 
 DatumPrestankaRada AS Expr1, VrstaUstanoveID AS Expr2
FROM dbo.Ustanova
WHERE (VrstaUstanoveID = 10) AND (DatumPrestankaRada > { fn NOW() })
Picture 8. Administrative prohibition measures imposed in the inspection supervision as of 01.01.2015: Source: http://www.almbih.
gov.ba/inspektorat/ visited: 28.11.2019.
Picture 7. Report Registry of manufacturers of Medicinal Products in Bosnia and Herzegovina source: http://www.almbih.gov.ba/_
doc/proizvodjaci/rpl.pdf?5 
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CONCLUSION
Establishing a database in the control of the 
pharmaceutical market in Bosnia and Herzegovina 
will facilitate cooperation and business in the ϐield 
of classiϐication and supervision of legal entities en-
gaged in the wholesale distribution of pharmaceuti-
cal and medical products.
Namely, databases in pharmacy are important 
for the classiϐication of data and for the monitor-
ing of the traceability of administrative proceedings 
and penalties against legal and natural persons who 
make offenses. We have seen in the paper that, in ad-
dition to being tracked, wholesale owners are also 
classiϐied by the type. Sometimes we have a situa-
tion where the owner tries to maximize proϐits at 
the expense of noncompliance and does not want 
to comply with the minimum legislative requests. 
Sometimes we have a situation where a healthcare 
professional, pharmacist or a doctor tries to maxi-
mize proϐits by breaking the rules. In both cases, 
there is a procedure that ϐirst points to the need to 
eliminate deϐiciencies and return within legal frame, 
and if he fails to comply with repressive measures 
in the form of penal provisions and other sanctions, 
and even prison sentences. Namely, repressive sanc-
tions are rigorous because the health of the popula-
tion is threatened.
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